Australia markets open in 5 hours 3 minutes

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
66.03-0.26 (-0.39%)
At close: 04:00PM EDT
66.06 +0.03 (+0.05%)
After hours: 07:07PM EDT
Full screen
Loading interactive chart…
  • Motley Fool

    3 Unstoppable Stocks That Don't Care About the Bear Market

    Whether it's thanks to a winning business model or timely good news, some companies are taking the bear market in stride, and some are even crushing it. Compared to the broader market's slump of around 5% in the last 12 months, AstraZeneca's (NASDAQ: AZN) stock has climbed 19%, making it a robust outperformer, to say the least. The company's success during the bear market is simply a matter of the strength of its drug development pipeline; with 184 projects in clinical trials and late-preclinical testing, it's among the largest in the world.

  • Business Wire

    ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer

    WILMINGTON, Del., August 06, 2022--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

  • Business Wire

    CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications

    WILMINGTON, Del., August 05, 2022--AstraZeneca’s new tablet formulation of CALQUENCE® (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under accelerated approval based on overall response rate.